<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844606</url>
  </required_header>
  <id_info>
    <org_study_id>16633</org_study_id>
    <secondary_id>I6T-MC-AMAZ</secondary_id>
    <secondary_id>2020-005311-49</secondary_id>
    <secondary_id>ISA-1 UC</secondary_id>
    <nct_id>NCT04844606</nct_id>
  </id_info>
  <brief_title>A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)</brief_title>
  <acronym>SHINE-ON</acronym>
  <official_title>A Master Protocol for a Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate the Long-term Efficacy and Safety of Mirikizumab in Children and Adolescents With Moderate-to-severe Ulcerative Colitis or Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in&#xD;
      pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will&#xD;
      last about 172 weeks and may include up to 44 visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">September 23, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with UC in Modified Mayo Score (MMS) Clinical Remission</measure>
    <time_frame>Week 52</time_frame>
    <description>Clinical Remission based on the Modified Mayo Score (MMS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with UC in MMS Clinical Remission</measure>
    <time_frame>Week 156</time_frame>
    <description>Clinical Remission based on the MMS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with UC in MMS Clinical Response</measure>
    <time_frame>Week 52</time_frame>
    <description>Clinical Response based on the MMS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with UC in Pediatric Ulcerative Colitis Activity Index (PUCAI) Clinical Response</measure>
    <time_frame>Week 52</time_frame>
    <description>Clinical Response based on the PUCAI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with UC in PUCAI Clinical Remission</measure>
    <time_frame>Week 52</time_frame>
    <description>Clinical Remission based on the PUCAI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with UC in Endoscopic Remission</measure>
    <time_frame>Week 52</time_frame>
    <description>Endoscopic Remission based on the Endoscopic Subscore (ES)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with UC in Endoscopic Response</measure>
    <time_frame>Week 52</time_frame>
    <description>Endoscopic Response based on the ES</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with UC in having Endoscopic Subscore = 0</measure>
    <time_frame>Week 52</time_frame>
    <description>Endoscopic Remission when ES=0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with UC Experiencing Histologic-Endoscopic Mucosal Remission</measure>
    <time_frame>Week 52</time_frame>
    <description>Histologic remission based on histology scoring and endoscopic subscore</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with UC in Corticosteroid-free Remission Without Surgery</measure>
    <time_frame>Week 52</time_frame>
    <description>Corticosteroid-free Remission based on MMS in participants who did not have an ulcerative colitis (UC)-related surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Body Weight</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Body weight change from baseline at Week 52 in participants with UC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height Velocity (in Centimeters/Year)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Height Velocity measured in centimeters/year in participants with UC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hormone levels at approximate 6-month intervals until growth is complete</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Estradiol or testosterone levels change from baseline at Week 52 in participants with UC</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>Ulcerative Colitis Chronic</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Mirikizumab Dose 1 for UC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 of Mirikizumab is administered subcutaneously (SC)&#xD;
Dosing is based on the assessments of the participant's weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirikizumab Dose 2 for UC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 of Mirikizumab is administered SC&#xD;
Dosing is based on the assessments of the participant's weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirikizumab Dose 3 for UC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 of Mirikizumab is administered SC&#xD;
Dosing is based on the assessments of the participant's weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirikizumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Mirikizumab Dose 1 for UC</arm_group_label>
    <arm_group_label>Mirikizumab Dose 2 for UC</arm_group_label>
    <arm_group_label>Mirikizumab Dose 3 for UC</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants from originating studies (I6T-MC-AMBU [NCT04004611]) who should, in the&#xD;
             opinion of the investigator, derive clinical benefit from further treatment with&#xD;
             mirikizumab&#xD;
&#xD;
          -  Participants from prior studies who have had at least one study drug administration&#xD;
             and have not had early termination of study drug.&#xD;
&#xD;
          -  Female participants must agree to contraception requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants must not have developed a new condition, including cancer in the&#xD;
             originator study.&#xD;
&#xD;
          -  Participants must not have any important infections including, but not limited to,&#xD;
             hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during either&#xD;
             originator study.&#xD;
&#xD;
          -  Participants must not have received surgery for UC in the originator study or are&#xD;
             likely to require surgery for treatment of UC during the study.&#xD;
&#xD;
          -  Participants must not require parenteral nutrition delivered by central vein and/or&#xD;
             central venous catheter for venous access.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLilly (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Medical Center at Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>415-476-5892</phone>
    </contact>
    <investigator>
      <last_name>Sofia G Verstraete</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jeffrey Hyams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MGH for Children - Waltham</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>111-111-1111</phone>
    </contact>
    <investigator>
      <last_name>Jess Kaplan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>682-885-1990</phone>
    </contact>
    <investigator>
      <last_name>Clifton Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Specialty Group, PPLC</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>757-668-7240</phone>
    </contact>
    <investigator>
      <last_name>Sameer Lapsia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition; Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>97226666666</phone>
    </contact>
    <investigator>
      <last_name>Dan Turner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical And Dental University Medical Hospital</name>
      <address>
        <city>Bunky≈ç</city>
        <state>Tokyo</state>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Masakazu Nagahori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/6Fqthjwf4KUkJi8EyTQv5A</url>
    <description>A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric Ulcerative Colitis</keyword>
  <keyword>Pediatric Crohn's Disease</keyword>
  <keyword>Pediatric UC</keyword>
  <keyword>Pediatric CD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirikizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

